CYP19A1 and breast cancer: SOLAR‐1 was a phase III, randomized, double‐blind, placebo‐controlled trial that investigated the effectiveness of the combination of fulvestrant and the α‐specific PI3K inhibitor alpelisib compared to placebo in patients with HR+, HER2–metastatic BC who had previously received treatment with aromatase inhibitors.20